Related Experiment Video
Updated: Feb 5, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Shubham Pant1, Joleen Hubbard2, Erika Martinelli3
1Department of Investigational Cancer Therapeutics and GI Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Abstract:
KRAS mutations are common in pancreatic and colorectal cancers and are associated with lack of response to anti-epidermal growth factor receptor therapy. Ras is an established therapeutic target that has long eluded efforts to develop specific inhibitors, while targeting downstream signaling pathways has proven largely ineffective, highlighting a need for rational combination strategies to overcome resistance. Recently, renewed interest in directly targeting Ras has led to the development of several small-molecule inhibitors that bind directly to K-Ras or its effector proteins, downregulation of K-Ras expression using therapeutic antisense oligonucleotides or siRNAs, and targeting scaffold proteins such as kinase suppressor of Ras. Indirect approaches to inhibiting K-Ras include combining inhibitors of the mitogen-activated protein kinase pathway with novel targeted agents. Immunotherapy in early studies has also shown clinical promise. This review summarizes the current evidence for each of these approaches.
Insights
Targeting KRAS mutations in pancreatic and colorectal cancers is challenging. This review explores new direct and indirect strategies, including small-molecule inhibitors and immunotherapy, to overcome resistance to anti-EGFR therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- KRAS mutations are prevalent in pancreatic and colorectal cancers.
- These mutations confer resistance to anti-epidermal growth factor receptor (EGFR) therapy.
- Existing downstream pathway inhibition strategies have shown limited efficacy.
Purpose of the Study:
- To review current and emerging therapeutic strategies targeting KRAS.
- To highlight the need for novel combination approaches to overcome resistance.
- To summarize evidence for direct and indirect KRAS inhibition methods.
Main Methods:
- Review of current scientific literature and clinical trial data.
- Analysis of direct KRAS inhibition strategies (small molecules, gene silencing).
- Evaluation of indirect approaches (MAPK pathway inhibitors, immunotherapy).
Main Results:
- Development of small-molecule inhibitors targeting K-Ras directly.
- Exploration of gene silencing techniques (siRNA, antisense oligonucleotides).
- Emerging promise of immunotherapy and combination strategies.
Conclusions:
- Directly targeting KRAS presents a promising avenue for cancer therapy.
- Combination strategies are crucial for overcoming resistance mechanisms.
- Further research into novel agents and immunotherapy is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38The Ras Gene
Ras is a...
01:24Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
01:26Anatomy of the Gastrointestinal System
Here's a detailed walkthrough of this complex system:
01:20Gastrointestinal Motility Disorders